Workers Compensation
Anxiety, low mood and poor sleep on a physical claim are often accepted as new secondary psychological conditions. Some are medication side effects, and telling the two apart decides whether the claim recovers or stalls.
Why are secondary psychological conditions rising on physical claims?
The scheme-level picture in NSW is well documented. SIRA's Return to Work Roadmap 2026-28 reports that the proportion of injured workers back at work at 13 weeks has fallen from 88% in 2016-17 to 79% in 2024-25, a decline SIRA estimates represents 45,680 additional people not working over that period. The window closes quickly: after 20 days off work the chance of return is 70%, and by 45 days it is 50%.
The tail is increasingly psychological. On the roadmap's figures, psychological claims make up around 10% of claims but 26% of scheme costs, and their 13 week return to work rate sits at just 40%, against 84% for physical injuries. Secondary psychological conditions accepted on physical claims sit inside that tail, and this is exactly where unrecognised medication effects surface.
Here is the pattern injury managers see on the file. A physical injury is managed with short course medicines in the acute phase. Months later, the worker reports fatigue, low mood, poor sleep or anxiety. Those symptoms are referred, diagnosed and accepted as a secondary psychological condition. From that point the scheme funds the diagnosis for the life of the claim. What rarely gets asked is whether the symptoms tracked the injury, or the prescription.
Which medication side effects get read as new conditions?
Every major guideline treats the common claim medications as short course medicines. A claimant still taking them at week 12 is already outside guideline, and the documented long-term effects of each class map closely onto the symptoms that become secondary diagnoses.
| Medicine | Guideline window for acute use | What continuation does over months | How it surfaces in a claim |
|---|---|---|---|
| Opioids | Ideally under 7 days for acute pain (ANZCA position statement, 2023) | Endocrine suppression: a 2020 systematic review found 63% of men on long term opioids met criteria for hypogonadism, driving fatigue, low mood and weight gain. Higher opioid load also predicts poorer rehabilitation outcomes. | Fatigue and low mood are read as depression. Stalled physiotherapy is read as poor motivation. |
| Benzodiazepines | 1 to 4 weeks (RACGP guidance) | Altered sleep architecture: deep and REM sleep are suppressed, so sleep is sedated but not restorative, with documented concentration and memory deficits. | Persistent insomnia and cognitive complaints present as new symptoms needing new treatment. |
| Z drugs | Maximum 4 weeks under the approved product information; SIRA notes long term use is not evidence based | The same pattern of tolerance, dependence and next day sedation, continued long past the approved window. | Ongoing sleep disturbance becomes a condition in its own right. |
| Pregabalin | Indicated for neuropathic pain, not general pain | The TGA actively monitors pregabalin for dependence, withdrawal and suicidality. Victorian ambulance attendances for pregabalin misuse rose more than tenfold between 2012 and 2017, and around 40% involved a suicide attempt. | Deteriorating mental health is attributed to the injury and accepted as a secondary condition. |
| Antidepressants started for a symptom | Close monitoring required in the first weeks after initiation | Regulators warn of elevated agitation and suicidality risk in the early weeks of treatment. Started for poor sleep or distress rather than a diagnosed condition, initiation effects are easily misread as the condition worsening. | A new diagnosis, and a new compensable claim head. |
The pattern in every row is the same. A medication effect surfaces, is read as a new condition, is diagnosed, and is accepted as a secondary compensable condition. Opioid side effects alone can account for the fatigue, flat mood and weight gain that anchor many secondary psychological claims.
What does the sequence on the file tell you?
The most useful evidence is already on the claim. Dispense histories, pharmacy receipts and clinical correspondence establish when each medication started, at what dose, and how long it has continued. Setting that timeline against the emergence of new symptoms answers the core question: did the secondary condition appear after a medication profile known to produce it?
The published Australian evidence shows how often that sequence is in play. A 2025 study of Australian workers compensation claims for back and neck disorders found one in five workers was dispensed an opioid within 90 days of injury, and two in three of those received early high risk prescribing. Earlier Australian claims research found around a third of workers who commence opioids progress to long term use, and that long term dispensing groups record median time off work approaching two and a half years. Workers still off work at three months are almost eight times more likely to develop persistent opioid use.
None of this is a criticism of treating doctors. Prescribers manage acute presentations competently, but within a system where no one is asked to hold the long-term medication plan. Each new symptom receives a new script, and the result is a prescribing cascade: symptoms treated downstream while the cause sits upstream, with each addition widening the adverse effect profile.
What should injury managers check before week 12?
Return to work outcomes are largely set in the first twelve weeks, so this is where the checks earn their keep. On any physical claim where the worker is still off work, four questions are worth asking before a secondary diagnosis lands:
- Is any short course medicine (opioid, benzodiazepine, z drug) still being dispensed past its guideline window?
- Have new symptoms (fatigue, low mood, poor sleep, anxiety, cognitive complaints) emerged after a medication started or a dose increased?
- Are medications being funded for conditions unrelated to the compensable injury, and does anyone hold the combined picture?
- Is treatment stalling in ways that fit sedation, such as missed physiotherapy or disengagement, rather than the injury itself?
A yes to any of these is a flag to look at the medication picture before accepting a new condition. On workers compensation claims the difference is financial as well as clinical: a side effect managed now is a cost that ends, while an accepted secondary diagnosis is funded for the life of the claim, often alongside independent medical examinations across multiple specialties.
When should you request an independent medication review?
The strongest trigger is timing: a claimant off work at week 12 with any short course medicine still running, or a secondary psychological or sleep condition proposed on a physical claim. At that point an independent medication review maps the full picture, sequences symptom emergence against prescribing, benchmarks each medicine against published guidance from ANZCA, the RACGP and SIRA's better practice guide, and gives the treating GP specific, actionable recommendations. The GP remains the sole prescriber throughout; the review adds the governance layer the file is missing, not another prescriber.
SIRA's medication management better practice guide already asks insurers to monitor high risk medications, including through medication review. The guidance exists. What the review supplies is the visibility to act on it, early enough that a manageable side effect never has to become a permanent diagnosis. That is the practical lever on return to work that sits inside almost every stalled claim.
Key Takeaways
- SIRA's Return to Work Roadmap 2026-28 shows 13 week return to work has fallen from 88% to 79%, with psychological claims carrying a disproportionate share of cost.
- Common claim medications are all short course medicines, and continuation past their guideline windows produces effects that mimic new psychological and sleep conditions.
- Sequencing symptom emergence against medication initiation is the single most useful check before accepting a secondary condition.
- A medication side effect is manageable now, while an accepted secondary diagnosis is funded for the life of the claim.
- Week 12 is the natural review point: still inside the intervention window, and already past every guideline window for acute medicines.
- An independent medication review adds governance and visibility while the treating GP remains the sole prescriber.
Frequently Asked Questions
How can an injury manager tell whether a secondary condition is a medication side effect?
Sequence the file. Check when each medication started, whether use has run past the guideline window, and whether the new symptoms emerged after a medication known to produce them. If the timeline lines up, request a pharmacist review before the diagnosis is accepted.
What are the guideline windows for common claim medications?
Opioids are recommended for ideally under 7 days in acute pain, benzodiazepines for 1 to 4 weeks, and z drugs for a maximum of 4 weeks under the approved product information. Antidepressants require close monitoring in the first weeks after initiation.
Does questioning a secondary condition mean disputing the claim?
No. The purpose is to treat the cause. If fatigue, low mood or poor sleep is a medication effect, adjusting the medication can resolve it. Accepting it as a new diagnosis funds it for the life of the claim without fixing the driver.
When is the best time to review the medication picture on a claim?
Before the 12 week mark. By then, short course medicines started in the acute phase are already outside guideline windows, and their effects are starting to be read as new conditions. A review at this point still sits inside the intervention window.
Primary source: State Insurance Regulatory Authority (SIRA), Return to Work Roadmap 2026-28 (2026) and Medication Management in the NSW Personal Injury Schemes: Better Practice Guide (2025).
